sPD1 and sPD-L1 have also been characterized as prognostic and/or predictive factors for immunotherapy response in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and renal cell carcinoma (RCC) [18–20]. Here, HOXD13 is linked to pancreatic ductal adenocarcinoma.